Core Insights - The DECIPHER-Omnia study, led by the company, has been published in the prestigious journal Nature Medicine, highlighting advancements in cancer early screening technology [1] - The company has developed a non-invasive blood test, MERCURY, which can screen for nine common cancers using a single blood sample, addressing significant limitations in current cancer screening methods [1] Group 1: Cancer Screening Technology - The current cancer screening methods are invasive, have low compliance, and poor accuracy, primarily covering a limited range of cancers such as lung, breast, and colorectal cancers [1] - The MERCURY technology utilizes ultra-low depth whole genome sequencing combined with AI models to analyze cfDNA fragments in blood, identifying unique tumor signals [1] Group 2: Research and Community Impact - The "Jinling Cohort" project, initiated by the company in collaboration with Nanjing Jiangbei New Area and Nanjing Medical University, has provided free comprehensive health checks to nearly 15,000 residents, totaling 25,000 tests [2] - The study shows a specificity (true negative rate) of 98.1% and a sensitivity (true positive rate) of 53.8%, with 91% of detected positive cases being in the early stages of cancer, significantly improving treatment opportunities [2] Group 3: Future Directions - The company plans to deepen collaboration with Nanjing Jiangbei New Area to promote the widespread application of cancer early screening technologies using genomics and big data analysis [2]